CLINICAL EFFICACY AND QUALITY OF LIFE WITH INDAPAMIDE ALONE OR IN COMBINATION WITH BETA-BLOCKERS OR ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS

被引:11
作者
ATHANASSIADIS, DI
DIMOPOULOS, CG
TSAKIRIS, AK
COKKINOS, DF
TOURKANTONIS, AA
TOUTOUZAS, PK
BOUTIN, B
GUEZ, D
机构
[1] TZANION GEN HOSP, DEPT CARDIOL & HYPERTENS, PIRAEUS, GREECE
[2] INST RECH INT SERVIER, NEUILLY SUR SEINE, FRANCE
[3] ARISTOTELIAN UNIV SALONIKA, ACHEPA HOSP, DEPT INTERNAL MED 1, Thessaloniki, GREECE
[4] UNIV ATHENS, HIPPOKRAT HOSP, DEPT CARDIOL, ATHENS, GREECE
关键词
D O I
10.1016/0002-9149(90)90346-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A multicenter study was performed to assess the efficacy and the acceptability of indapamide in hypertensive patients previously untreated, or treated and unsatisfactorily controlled with either angiotensin-converting enzyme (ACE) inhibitor or β-blocking therapy. Four centers participated in the study, which included patients whose supine diastolic blood pressure was between 95 and 115 mm Hg with no treatment (group I, n = 40), those taking captopril (group II, n = 40) or those taking propranolol (group III, n = 40). After a 2-week single-blind placebo run-in period, patients received indapamide either alone (group I) or in combination with the previous therapy (groups II and III) for 4 months. Blood pressure, heart rate, weight, and clinical and biochemical acceptability were measured before and after 2 and 4 months of treatment. At the same time points, quality of life was determined using standardized questionnaires completed by the patient (20 items) and the physician (10 items) and a visual analog scale completed by the patient. In all groups, administration of indapamide induced a clinically and statistically significant reduction in both systolic and diastolic blood pressures in the supine position after 2 months. Indapamide atone controlled blood pressure in 82% of the patients previously untreated, and indapamide in combined therapy controlled blood pressure, respectively, in 67 and 85% of patients previously uncontrolled with ACE inhibitors or β blockers. In all groups, questionnaires on quality of life showed a progressive and significant improvement in general well-being. After 4 months of treatment, the percentage of improvement in the physician questionnaire was 77.1% in group I, 60.6% in group II and 71.4% in group III. Similar results were obtained with the patient questionnaire. Biochemical acceptability was characterized by the stability of all parameters, including sodium, potassium, glucose, creatinine, cholesterol and triglycerides and a slight increase in uric acid in all groups. These results confirm the satisfactory efficacy and acceptability of indapamide and its beneficial effects on quality of life when administered as a first-step therapy as well as in combination with β blockers or ACE inhibitors. © 1990.
引用
收藏
页码:H62 / H66
页数:5
相关论文
共 20 条
[11]  
Guez D, 1988, Am J Med, V84, P53
[12]  
KUBIK MM, 1981, POSTGRAD MED J, V57, P44
[13]  
Lacourciere Y, 1988, Am J Med, V84, P47
[14]  
Leonetti G, 1988, Am J Med, V84, P59
[15]   ADVANTAGES AND LIMITATIONS OF DIURETIC THERAPY IN ESSENTIAL-HYPERTENSION [J].
LEONETTI, G ;
TERZOLI, L ;
BRAGATO, R .
AMERICAN JOURNAL OF HYPERTENSION, 1989, 2 (02) :S82-S85
[16]  
MEYERSABELLEK W, 1985, HYPERTENSION, V7, P170
[17]   TREATING HYPERTENSION - A REVIEW OF CLINICAL-TRIALS [J].
MOSER, M .
AMERICAN JOURNAL OF MEDICINE, 1986, 81 (6C) :25-32
[18]   INDAPAMIDE VERSUS BETA-BLOCKER THERAPY - A DOUBLE-BLIND, CROSSOVER STUDY IN ESSENTIAL-HYPERTENSION [J].
RUMBOLDT, Z ;
RUMBOLDT, M ;
JURISIC, M .
CURRENT MEDICAL RESEARCH AND OPINION, 1984, 9 (01) :10-20
[19]  
SCALABRINO A, 1984, CURR THER RES CLIN E, V35, P17
[20]  
WEIDMANN P, 1983, HYPERTENSION, V5, P120